Pharmaceutical News Wrap Up: April 2014

Here at the Firm, our pharmaceutical lawyers are committed to keeping you on track with the latest pharmaceutical news. Below is a short list of some of the most recent headlines concerning FDA recalls, approvals and warning label changes, medical studies and other pharmaceutical news taking place across the country and world.

  • As testosterone use grows, questions on risks await answers
    While recent studies link testosterone therapy to increased risk of heart attack, stroke or death, questions about its risks still remain as more studies are needed. Peter J. Snyder of the University of Pennsylvania is leading a study due next year.
  • Takeda shares drop after report on $6 billion jury award over Actos
    After a jury ordered pharmaceutical manufacturer Takeda to pay $6 billion in punitive damages over its Actos diabetes drug, shares in the company were down 6 percent. This is a six-month low for the company.
  • FDA warns consumers of harmful ingredients in weight loss capsules
    The U.S. Food and Drug Administration is warning consumers about the harmful ingredients in Zi Xiu Tang Bee Pollen weight loss and body reshaping supplements. According to the agency, the supplements contain at least one dangerous ingredient not listed on the product label and consumers should discontinue use immediately.
Simmons Support Team
Simmons Hanly ConroyWritten by:

Editorial Team

The Simmons Hanly Conroy Editorial Team consists of journalists, writers and editors who strive to deliver accurate and useful information to families needing legal help. Our team works alongside the firm's attorneys and partners, as well as with medical professionals and other specialists, to keep all information relevant and helpful.